1. Introduction {#sec1-ijerph-15-00153}
===============

*Acinetobacter* species (spp.) are Gram-negative coccobacilli that cause serious healthcare-associated infections like ventilator-associated pneumoniae, blood stream infections, urinary tract infections, and wound infections in critically ill patients \[[@B1-ijerph-15-00153],[@B2-ijerph-15-00153]\]. Community-acquired infections like skin and soft tissue infections in relation to trauma are also caused by the genus *Acinetobacter* \[[@B1-ijerph-15-00153]\]. The bacterium *Acinetobacter baumannii* is the most clinically important of the bacteria belonging to this genus \[[@B3-ijerph-15-00153]\]. During the last three decades *A. baumannii* isolates have become resistant to more and more classes of antibiotics due to both intrinsic and acquired resistance mechanisms \[[@B2-ijerph-15-00153],[@B4-ijerph-15-00153]\]. For a long time carbapenems was the most reliable treatment option for infections caused by *Acinetobacter* spp., but carbapenemase-producing isolates are emerging globally \[[@B2-ijerph-15-00153],[@B5-ijerph-15-00153]\]. Alternative treatment options are the last-resort drugs polymyxins (colistin or polymyxin B) and tigecycline, or a combination of one of these classes with a second agent \[[@B2-ijerph-15-00153],[@B6-ijerph-15-00153],[@B7-ijerph-15-00153]\]. *Acinetobacter* spp. isolates that are resistant to colistin or polymyxin B have been reported worldwide \[[@B8-ijerph-15-00153],[@B9-ijerph-15-00153]\]. Due to the rising levels of resistant isolates therapeutic options are limited or even absent in some cases of infections with pandrug-resistant bacteria. *Acinetobacter* spp. are adapted to persistence in hospital settings and are difficult to eradicate \[[@B2-ijerph-15-00153]\]. Infections caused by *Acinetobacter* spp. are associated with increased mortality \[[@B10-ijerph-15-00153],[@B11-ijerph-15-00153]\], increased length of hospital stay \[[@B11-ijerph-15-00153]\], and higher costs \[[@B12-ijerph-15-00153]\]. The high prevalence of resistant isolates towards many classes of antibiotics makes initiation of effective empiric treatment challenging \[[@B13-ijerph-15-00153]\]. It is of great importance with local and national surveillance data on the prevalence of resistant *Acinetobacter* spp. isolates, both to inform local treatment guidelines and to detect outbreaks and changes in trends. Both regional and national surveillance systems are lacking in India. Hence, there is great need for long-term studies on the proportions and trends in antibiotic resistance among *Acinetobacter* spp. isolates to gain more knowledge about the development and spread of antibiotic resistance in India. In this study we have examined the proportions of and trends in multidrug-resistance (MDR) among *Acinetobacter* spp. isolates from the district of Nashik in Western India during the period 2011--2014.

2. Materials and Methods {#sec2-ijerph-15-00153}
========================

2.1. Study Setting {#sec2dot1-ijerph-15-00153}
------------------

Antibacterial susceptibility testing of clinical *Acinetobacter* spp. isolates were performed at the Bac-Test Laboratory, an ISO certified laboratory that serves various hospitals, clinics and diagnostic laboratories in the district of Nashik \[[@B14-ijerph-15-00153]\]. The district belongs to the state of Maharashtra in the western part of India and has a population of more than 6.1 million and covers an area of 15,582 km^2^ \[[@B15-ijerph-15-00153]\].

2.2. Study Material {#sec2dot2-ijerph-15-00153}
-------------------

The data were collected in the period from 1 January 2011 to 31 December 2014. Information about type of patient (in- or outpatient), type of specimen (blood, respiratory etc.), date of specimen collection, and the results of the antibacterial susceptibility testing for every isolate were recorded in the WHONET software \[[@B16-ijerph-15-00153]\]. The data were collected at the genus level and not the species level. The data material consisted of a total of 763 *Acinetobacter* spp. isolates. Eighteen isolates were excluded due to lack of information about patient type, and another four isolates were excluded since they were tested for less than three antibacterial categories (see definition of MDR in the [Section 2.4](#sec2dot4-ijerph-15-00153){ref-type="sec"}. Statistical analyses). Hence, the final data set consisted of 741 *Acinetobacter* spp. isolates.

The data material used in this study was retrospective data from routine analysis of antibacterial susceptibilities. The data were anonymous since no patient identifiers were available, and it would therefore not be possible to obtain informed consent from the patients.

2.3. Laboratory Methods {#sec2dot3-ijerph-15-00153}
-----------------------

Antibiotic susceptibility testing was performed using the Kirby--Bauer disk diffusion method (with disks from HiMedia Laboratories, Mumbai, India and Becton, Dickinson, Franklin Lakes, NJ, USA) according to the most updated Clinical and Laboratory Standards Institute (CLSI) guideline at the time of analysis \[[@B17-ijerph-15-00153],[@B18-ijerph-15-00153],[@B19-ijerph-15-00153]\]. The double disk synergy test was used to screen for extended-spectrum β-lactamase (ESBL)-producing isolates \[[@B17-ijerph-15-00153]\].

2.4. Statistical Analyses {#sec2dot4-ijerph-15-00153}
-------------------------

The recorded inhibitory zone diameters were interpreted according to the clinical zone diameter breakpoints provided by the CLSI guideline used at the time of the antibacterial susceptibility testing \[[@B17-ijerph-15-00153]\]. Susceptible bacterial isolates were classified as "susceptible", whereas intermediate susceptible and resistant bacterial strains were classified as "non-susceptible". Multidrug resistance (MDR) was defined using the criteria proposed by the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) \[[@B20-ijerph-15-00153]\]. According to the criteria and available data in the data set, an *Acinetobacter* spp. isolate was classified as MDR if the isolate was non-susceptible to at least one antibacterial agent in at least three of the following antibacterial categories; aminoglycosides (gentamicin, tobramycin, or amikacin), carbapenems (imipenem, meropenem, or doripenem), fluoroquinolones (ciprofloxacin or levofloxacin), antipseudomonal penicillins/β-lactamase inhibitors (piperacillin-tazobactam or ticarcillin-clavulanic acid), cephalosporins (cefotaxime, ceftriaxone, ceftazidime, or cefepime), folate pathway inhibitors (trimethoprim-sulphamethoxazole), penicillins/β-lactamase inhibitors (ampicillin-sulbactam), and tetracyclines (tetracycline or doxycycline). Polymyxins (colistin or polymyxin B) were not included in the analyses due to lack of clinical breakpoints in the CLSI guideline \[[@B17-ijerph-15-00153]\]. Non-susceptibility to an antibacterial category was defined as being non-susceptible to at least one antibacterial agent in an antibacterial category \[[@B20-ijerph-15-00153]\]. Changes in clinical zone diameter breakpoints for meropenem and imipenem in 2014 were taken into account when classifying the isolates as "susceptible" or "non-susceptible". No clinical zone diameter breakpoints were available for doripenem before 2014. For the isolates tested for susceptibility to doripenem in the period from 2011--2013, the clinical zone diameter breakpoints for meropenem and imipenem in the same period were used.

Proportions of non-susceptible isolates (number of non-susceptible isolates as a proportion of total isolates tested) were calculated from the antibacterial susceptibility data. Calculated proportions of non-susceptible isolates were compared between inpatients and outpatients, and between various specimen types using Chi square tests. A two-sided *p*-value \< 0.05 was considered statistically significant. Odds ratios (ORs) of non-susceptible isolates associated with 1-year increment in the period 2011--2014 were estimated along with 95% confidence intervals using logistic regression.

Statistical analyses were performed using Stata version 14 (Stata Corp., College Station, TX, USA).

3. Results {#sec3-ijerph-15-00153}
==========

3.1. Acinetobacter spp. Isolates {#sec3dot1-ijerph-15-00153}
--------------------------------

Out of the 741 *Acinetobacter* spp. isolates included in the study, the majority of the isolates were obtained from the respiratory system (50.7%; includes samples from bronchoalveolar lavage, sputum, throat and trachea), followed by pus (18.3%) and blood (15.4%) samples. Inpatients and outpatients contributed to 88.5% and 11.5% of the samples, respectively.

3.2. High Proportions of MDR Acinetobacter spp. Isolates during the Period from 2011--2014 {#sec3dot2-ijerph-15-00153}
------------------------------------------------------------------------------------------

The proportions of MDR isolates ranged from 89.4% to 95.9% in the study period ([Figure 1](#ijerph-15-00153-f001){ref-type="fig"}A and [Table A1](#ijerph-15-00153-t0A1){ref-type="table"}). For isolates that tested positive for ESBL, the proportions ranged from 87.9% to 94.0% ([Figure 1](#ijerph-15-00153-f001){ref-type="fig"}B and [Table A1](#ijerph-15-00153-t0A1){ref-type="table"}). High proportions of non-susceptible isolates were found for the antibacterial categories aminoglycosides (84.7--91.0%), carbapenems (81.6--88.3%), antipseudomonal penicillins/β-lactamase inhibitors (85.1--95.3%), folate pathway inhibitors (88.7--93.1%), and penicillins/β-lactamase inhibitors (77.5--93.7%) ([Figure 2](#ijerph-15-00153-f002){ref-type="fig"} and [Table A1](#ijerph-15-00153-t0A1){ref-type="table"}). For cephalosporins, the proportions of non-susceptible isolates were found to be even higher, ranging from 95.7% to 97.7% ([Figure 2](#ijerph-15-00153-f002){ref-type="fig"}E and [Table A1](#ijerph-15-00153-t0A1){ref-type="table"}). The proportions of non-susceptible isolates to fluoroquinolones and tetracyclines were found to range from 65.3% to 83.3% and from 71.3% to 75.9%, respectively ([Figure 2](#ijerph-15-00153-f002){ref-type="fig"}C,H, and [Table A1](#ijerph-15-00153-t0A1){ref-type="table"}). The distributions of the inhibitory zone diameters for the antibacterial agents are shown in [Figure A1](#ijerph-15-00153-f0A1){ref-type="fig"}.

When comparing the proportions of MDR and ESBL-producing isolates between inpatients and outpatients, no statistically significant differences were found ([Table 1](#ijerph-15-00153-t001){ref-type="table"}). A higher proportion of non-susceptible isolates to aminoglycosides (*p* = 0.008) and antipseudomonal penicillins/β-lactamase inhibitors (*p* = 0.048) were found in inpatients. For the other antibacterial categories, no statistically significant differences between inpatients and outpatients were found ([Table 1](#ijerph-15-00153-t001){ref-type="table"}). Significantly higher proportions of non-susceptible, MDR and ESBL-producing isolates were found among isolates from the respiratory system compared to isolates from all other specimen types (*p* \< 0.05, [Table 2](#ijerph-15-00153-t002){ref-type="table"}).

3.3. No Change in Trends of MDR Acinetobacter spp. Isolates during the Period from 2011--2014 {#sec3dot3-ijerph-15-00153}
---------------------------------------------------------------------------------------------

An analysis of trends using logistic regression revealed that there were no changes in trends for MDR and ESBL-producing isolates ([Table 3](#ijerph-15-00153-t003){ref-type="table"}). No changes in trends were also observed for non-susceptibility to all antibacterial categories except for fluoroquinolones. Per every year increment in the period from 2011--2014 there was a 25% decrease in the probability of an *Acinetobacter* spp. isolate being non-susceptible to fluoroquinolones (OR = 0.75 (95% CI, 0.62--0.91)) ([Table 3](#ijerph-15-00153-t003){ref-type="table"}). When stratifying on type of specimen (respiratory samples versus samples from other specimen types), there was a 40% decrease in the probability of an isolate being non-susceptible to fluoroquinolones for the respiratory samples (OR = 0.60 (95% CI, 0.43--0.84)) ([Figure 2](#ijerph-15-00153-f002){ref-type="fig"}C). No change in trend for fluoroquinolone non-susceptibility was observed for the samples from other specimen types (OR = 0.82 (95% CI, 0.65--1.04) ([Figure 2](#ijerph-15-00153-f002){ref-type="fig"}C). In the period from 2011--2014, there was a higher proportion of respiratory samples, as well as a slightly higher proportion of samples from inpatients, collected towards the end of the period compared to samples from other specimen types and outpatients ([Table A2](#ijerph-15-00153-t0A2){ref-type="table"}).

For MDR and ESBL-producing isolates, as well as all other antibacterial categories, no differences in trends were observed for respiratory samples compared to samples from other specimen types ([Figure 1](#ijerph-15-00153-f001){ref-type="fig"} and [Figure 2](#ijerph-15-00153-f002){ref-type="fig"}).

4. Discussion {#sec4-ijerph-15-00153}
=============

In this study we have analyzed data on antibacterial susceptibility over a four years period among *Acinetobacter* spp. isolates from healthcare-associated- and community-acquired infections in the district of Nashik in Western India. We found high proportions of MDR and ESBL-producing isolates, as well as high proportions of non-susceptible isolates to aminoglycosides, carbapenems, fluoroquinolones, antipseudomonal penicillins/β-lactamase inhibitors, cephalosporins, folate pathway inhibitors, penicillins/β-lactamase inhibitors, and tetracyclines.

No changes in non-susceptibility trends were observed in the period from 2011--2014, except for fluoroquinolone non-susceptible isolates where we found a decreasing trend over time. The decreasing trend in fluoroquinolone non-susceptible isolates could possibly be explained by a change in type of sample collected over time, particularly a reduction in the proportions of respiratory samples for which we found significantly higher proportions of fluoroquinolone non-susceptible isolates ([Table 2](#ijerph-15-00153-t002){ref-type="table"}). However, in the period from 2011--2014, the proportions of respiratory samples tested for fluoroquinolone non-susceptibility rather increased ([Table A2](#ijerph-15-00153-t0A2){ref-type="table"}). When stratifying on type of specimen, we found a decreasing trend among isolates from the respiratory samples that explains the decreasing trend observed for all isolates tested for fluoroquinolone non-susceptibility. Since a decreasing trend was observed for the respiratory samples despite an increased sampling of the specimen type, the finding might reflect a true drop in fluoroquinolone non-susceptible isolates among respiratory samples. An explanation for the decreasing trend observed could be due to decreasing use of fluoroquinolones to treat respiratory infections. We did not have data on antibiotic consumption, neither from the individual patient nor at the aggregated level from the district of Nashik, so this will only be a speculation.

More surveillance data over a longer time period are needed to be able to conclude whether there is a steady decrease in the proportion of fluoroquinolone non-susceptible isolates or whether there will be an increase in the proportions of fluoroquinolone non-susceptible isolates in the coming years. Fluctuating proportions of resistant *Acinetobacter* spp. isolates over time has been observed in other long-term studies \[[@B21-ijerph-15-00153],[@B22-ijerph-15-00153],[@B23-ijerph-15-00153],[@B24-ijerph-15-00153],[@B25-ijerph-15-00153]\]. In another study on antibacterial susceptibility over an 11 years period among *E. coli* and *Klebsiella* spp. isolates from the district of Nashik we also found fluctuating trends in resistance over time (unpublished results). The fluctuating trends might reflect differences in the annual burden of infections or changes over time in the choice of empiric drugs for treatment of infections. The decision on which antibiotic to choose can also be influenced by external factors like drug price, drug availability and drug promotion practices. Information about these factors is difficult to obtain and were not available in our study.

The majority of the *Acinetobacter* spp. isolates were obtained from respiratory samples. This finding is consistent with the distribution of specimen types among *Acinetobacter* spp. isolates found in other studies \[[@B26-ijerph-15-00153],[@B27-ijerph-15-00153],[@B28-ijerph-15-00153],[@B29-ijerph-15-00153],[@B30-ijerph-15-00153],[@B31-ijerph-15-00153],[@B32-ijerph-15-00153]\]. The high prevalence of respiratory samples in our data indicates that *Acinetobacter* spp. most frequently cause respiratory disease in this setting. We found significantly higher proportions of MDR, ESBL-producing and non-susceptible isolates among isolates from the respiratory system compared to isolates from other specimen types. One explanation for the higher prevalence of MDR isolates from respiratory samples could be that the *Acinetobacter* strains causing ventilator-associated pneumonia or other healthcare-associated pneumoniae are more frequently exposed to antibiotics compared to strains causing other types of infection. Although we found significantly higher proportions of MDR isolates from respiratory samples, the proportions of MDR isolates from other specimen types were still high, which indicates that empiric treatment of all types of infections caused by *Acinetobacter* spp. is difficult.

*Acinetobacter* spp. have a natural MDR phenotype \[[@B33-ijerph-15-00153]\]. High proportions of MDR and ESBL-producing isolates were found in our study, and increasing and high proportions of MDR *Acinetobacter* spp. isolates have also been reported globally \[[@B24-ijerph-15-00153],[@B34-ijerph-15-00153],[@B35-ijerph-15-00153]\]. Of particular concern is the high proportion of carbapenem non-susceptible isolates observed throughout the study period. Another study from a tertiary care center in Pune, also in Western India, reported 42% carbapenem-resistant *Acinetobacter* spp. isolates from patients admitted to the intensive care unit in the period 2011--2013 \[[@B28-ijerph-15-00153]\]. Carbapenem resistance rates in *Acinetobacter* spp. isolates from other regions of India have been reported to be from 67% to 74% in the period 2009--2013 \[[@B21-ijerph-15-00153]\], from 0% to 84% in the period 2002--2008 \[[@B36-ijerph-15-00153]\], and 32% in the period 2010--2011 \[[@B25-ijerph-15-00153]\]. As opposed to our study, these studies are single-site studies. Our data material cover clinical *Acinetobacter* spp. isolates from a large number of clinics and hospitals in the district of Nashik, and reflect the resistance proportions in a larger region. The high proportions of carbapenem non-susceptible isolates in the district of Nashik indicate that carbapenems often will be inappropriate as empiric therapy to treat infections caused by *Acinetobacter* spp. in this region. A recent study from the U.S. found that the risk for acquisition of carbapenem-resistant *A. baumannii* in a hospital-setting quadrupled with carbapenem exposure \[[@B37-ijerph-15-00153]\], indicating that carbapenem restriction in combination with infection control measures are important to reduce the prevalence of highly resistant infections caused by *Acinetobacter* spp. *Acinetobacter* spp. infections are most often acquired in hospitals in severely ill patients, and community-acquired infections are rare \[[@B33-ijerph-15-00153]\]. Community-acquired pneumonia caused by *Acinetobacter* spp. have been associated with underlying factors, such as alcoholism, smoking, chronic obstructive pulmonary disease and diabetes \[[@B33-ijerph-15-00153]\]. In our study, the majority of isolates (88.5%) came from inpatients. When comparing the proportions of MDR *Acinetobacter* spp. isolates from inpatients and outpatients, no statistically significant difference was found. When comparing non-susceptible isolates to the various antibacterial categories, no differences were found except for higher proportions of non-susceptible isolates to aminoglycosides and antipseudomonal penicillins/β-lactamase inhibitors in inpatients compared to outpatients. Other studies have reported higher rates of susceptibility in isolates derived from the outpatient settings compared to isolates derived from hospitals and nursing homes \[[@B32-ijerph-15-00153],[@B38-ijerph-15-00153],[@B39-ijerph-15-00153]\]. If these isolates represent true community-acquired infections, the non-susceptibility proportions found among outpatients were alarmingly high.

Strengths and Limitations
-------------------------

The data analyzed in this study are unique, since longitudinal surveillance data from India are scarce. The data were collected over a four years period and analyzed at the same laboratory. Although there could be changes in staff and laboratory practices over time, the fact that the same laboratory performed all antibacterial susceptibility testing minimizes the risk for bias due to methodological issues. A limitation of this study is that all the isolates were not tested for all the antibacterial categories. Hence, there is a possibility for both underestimation and overestimation of the proportions of MDR and non-susceptible isolates due to lack of information about antibacterial susceptibilities to all categories for all isolates. However, more than 95% of the isolates were tested for the antibacterial categories aminoglycosides, carbapenems, antipseudomonal penicillins/β-lactamase inhibitors, or cephalosporins (see legend to [Figure 2](#ijerph-15-00153-f002){ref-type="fig"}). We were unable to determine whether the isolates were extensively drug-resistant (XDR) or pan-drug resistant (PDR) due to lack of information about antibacterial susceptibilities for all antibacterial categories for all isolates included in the study. Also, clinical breakpoints (inhibitory zone diameters) for polymyxins were lacking in the CLSI guideline \[[@B17-ijerph-15-00153]\]. Hence, information about antibacterial susceptibilities to all nine antibacterial categories that ECDC and CDC recommend to analyze in order to determine the prevalence of XDR and PDR isolates was not available in this study \[[@B20-ijerph-15-00153]\].

5. Conclusions {#sec5-ijerph-15-00153}
==============

This study highlights the high prevalence of MDR among clinical *Acinetobacter* spp. isolates in a district in Western India. The emergence of MDR *Acinetobacter* spp. is a serious global threat to public health. Both local and national surveillance data, as well as strict infection control and antimicrobial stewardship are needed to combat infections caused by MDR *Acinetobacter* spp.
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###### 

Proportions (%) of non-susceptible *Acinetobacter* spp. isolates according to multidrug resistance, antibacterial category and year.

  Multidrug Resistance/Antibacterial Category          2011   2012      2013   2014                              
  ---------------------------------------------------- ------ --------- ------ --------- ------ --------- ------ ---------
  Multidrug resistance                                 \%     *n* ^1^   \%     *n* ^1^   \%     *n* ^1^   \%     *n* ^1^
  MDR                                                  91.1   169       95.5   201       95.9   220       89.4   151
  ESBL                                                 87.9   157       90.5   190       94.0   201       90.9   142
  Antibacterial category                                                                                         
  Aminoglycosides                                      85.8   169       91.0   199       89.6   211       84.7   137
  Carbapenems                                          81.6   168       86.1   201       87.6   218       88.3   145
  Fluoroquinolones                                     83.3   96        83.3   126       65.3   216       72.9   140
  Antipseudomonal penicillins/β-lactamase inhibitors   85.1   161       92.3   195       95.3   212       88.7   142
  Cephalosporins                                       97.0   168       97.4   194       97.7   219       95.7   141
  Folate pathway inhibitors                            88.7   106       92.3   117       90.2   132       93.1   101
  Penicillins/β-lactamase inhibitors                   80.7   155       91.9   173       93.7   205       77.5   142
  Tetracyclines                                        74.6   63        71.4   98        71.3   136       75.9   108

^1^ *n* = total number of *Acinetobacter* spp. isolates.
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###### 

Proportions (%) of *Acinetobacter* spp. isolates from inpatients and respiratory samples tested for fluoroquinolone non-susceptibility per year.

  Type of Patient/Specimen Type   2011   2012     2013   2014                       
  ------------------------------- ------ -------- ------ ------ ------ ----- ------ -----
  Inpatients                      88.5   96       81.0   126    86.1   216   90.7   140
  Respiratory samples             39.0   95 ^2^   39.7   126    61.1   216   47.1   140

^1^ *n* = total number of *Acinetobacter* spp. isolates tested for fluoroquinolone non-susceptibility; ^2^ One missing value on specimen type.

![Proportions of multidrug-resistant (MDR) (**A**) and extended-spectrum β-lactamase (ESBL)-producing (**B**) *Acinetobacter* spp. isolates. The data were fitted with a logistic regression model (solid line = all isolates, long dashes = isolates from respiratory samples, short dashes = isolates from all other specimen types). Each bubble shows the proportion of isolates per year in the period from 2011--2014. The size of the bubbles represents the sample size (see [Table A1](#ijerph-15-00153-t0A1){ref-type="table"}). The total numbers of isolates tested for MDR and ESBL were 741 and 690, respectively.](ijerph-15-00153-g001){#ijerph-15-00153-f001}

![Proportions of non-susceptible *Acinetobacter* spp. isolates according to antibacterial category and year. The antibacterial categories were aminoglycosides (**A**, *n* = 716), carbapenems (**B**, *n* = 732), fluoroquinolones (**C**, *n* = 578), antipseudomonal penicillins/β-lactamase inhibitors (**D**, *n* = 710), cephalosporins (**E**, *n* = 722), folate pathway inhibitors (**F**, *n* = 456), penicillins/β-lactamase inhibitors (**G**, *n* = 675), and tetracyclines (**H**, *n* = 405). The data were fitted with a logistic regression model (solid line = all isolates, long dashes = isolates from respiratory samples, short dashes = isolates from all other specimen types). Each bubble shows the proportion of isolates per year. The size of the bubbles represents the sample size (see [Table A1](#ijerph-15-00153-t0A1){ref-type="table"}). *n* = total number of isolates in the period 2011--2014.](ijerph-15-00153-g002){#ijerph-15-00153-f002}
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###### 

Proportions (%) of non-susceptible *Acinetobacter* spp. isolates from inpatients and outpatients according to multidrug resistance and Antibacterial category in the period from 2011--2014.

  Multidrug Resistance/Antibacterial Category          Inpatients   Outpatients   *p* ^1^             
  ---------------------------------------------------- ------------ ------------- --------- --------- -------
  Multidrug resistance                                 \%           *n* ^2^       \%        *n* ^2^   
  MDR                                                  93.6         656           91.8      85        0.522
  ESBL                                                 91.3         611           88.6      79        0.427
  Antibacterial category                                                                              
  Aminoglycosides                                      89.3         634           79.3      82        0.008
  Carbapenems                                          86.3         649           83.1      83        0.437
  Fluoroquinolones                                     74.6         500           70.5      78        0.444
  Antipseudomonal penicillins/β-lactamase inhibitors   91.6         631           84.8      79        0.048
  Cephalosporins                                       97.2         638           96.4      84        0.701
  Folate pathway inhibitors                            90.4         385           94.4      71        0.282
  Penicillins/β-lactamase inhibitors                   87.4         596           82.3      79        0.205
  Tetracyclines                                        72.7         341           75.0      64        0.707

^1^ *p* \< 0.050 (Chi square test, 2-tailed) indicates statistical significance of the differences in non-susceptibility rates; ^2^ *n* = total number of *Acinetobacter* spp. isolates.
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###### 

Proportions (%) of non-susceptible *Acinetobacter* spp. isolates from different specimen types according to multidrug resistance and antibacterial category in the period from 2011--2014.

  Multidrug Resistance/Antibacterial Category          Respiratory ^1^   Other ^2^   *p* ^3^             
  ---------------------------------------------------- ----------------- ----------- --------- --------- ---------
  Multidrug resistance                                 \%                *n* ^4^     \%        *n* ^4^   
  MDR                                                  96.5              375         90.1      364       \<0.001
  ESBL                                                 95.5              355         86.2      333       \<0.001
  Antibacterial category                                                                                 
  Aminoglycosides                                      93.9              359         82.3      355       \<0.001
  Carbapenems                                          92.4              370         79.2      360       \<0.001
  Fluoroquinolones                                     78.3              285         69.9      292       0.022
  Antipseudomonal penicillins/β-lactamase inhibitors   96.4              357         85.2      351       \<0.001
  Cephalosporins                                       99.2              366         94.9      354       0.001
  Folate pathway inhibitors                            94.1              203         88.5      252       0.038
  Penicillins/β-lactamase inhibitors                   91.6              346         82.0      327       \<0.001
  Tetracyclines                                        80.6              191         66.2      213       0.001

^1^ Samples from the respiratory system (bronchoalveolar lavage, sputum, throat and trachea); ^2^ Other samples (including blood and pus); ^3^ *p* \< 0.050 (Chi square test, 2-tailed) indicates statistical significance of the differences in non-susceptibility rates; ^4^ *n* = total number of *Acinetobacter* spp. isolates
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###### 

Odds ratios (OR) with 95% confidence intervals (CI) of non-susceptible *Acinetobacter* spp. isolates for every year increase in the period from 2011--2014 from a logistic regression model.

  Multidrug Resistance/Antibacterial Category          OR     95% CI
  ---------------------------------------------------- ------ ------------
  Multidrug resistance                                        
  MDR                                                  0.95   0.72--1.25
  ESBL                                                 1.18   0.92--1.52
  Antibacterial category                                      
  Aminoglycosides                                      0.97   0.78--1.20
  Carbapenems                                          1.20   0.98--1.47
  Fluoroquinolones                                     0.75   0.62--0.91
  Antipseudomonal penicillins/β-lactamase inhibitors   1.22   0.95--1.56
  Cephalosporins                                       0.90   0.60--1.37
  Folate pathway inhibitors                            1.14   0.84--1.53
  Penicillins/β-lactamase inhibitors                   0.97   0.78--1.20
  Tetracyclines                                        1.03   0.83--1.28

[^1]: Contributed equally.
